CHF26.60
2.06% today
SIX Swiss Exchange, Aug 08, 02:18 pm CET
ISIN
CH0325814116
Symbol
KURN

Kuros Biosciences Stock price

CHF27.16
-1.60 5.56% 1M
+4.86 21.79% 6M
+5.81 27.21% YTD
+15.24 127.85% 1Y
+25.17 1,261.40% 3Y
+24.90 1,101.77% 5Y
-15.68 36.60% 10Y
-3,753.19 99.28% 20Y
SIX Swiss Exchange, Closing price Thu, Aug 07 2025
-0.26 0.95%
ISIN
CH0325814116
Symbol
KURN
Industry

Key metrics

Basic
Market capitalization
CHF1.0b
Enterprise Value
CHF993.0m
Net debt
positive
Cash
CHF17.9m
Shares outstanding
37.9m
Valuation (TTM | estimate)
P/E
negative | -
P/S
13.4 | 8.7
EV/Sales
13.3 | 8.5
EV/FCF
494.0
P/B
17.3
Financial Health
Equity Ratio
69.5%
Return on Equity
-7.3%
ROCE
-7.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
CHF74.9m | CHF121.7m
EBITDA
CHF-2.3m | CHF15.8m
EBIT
CHF-5.0m | -
Net Income
CHF-4.3m | -
Free Cash Flow
CHF2.0m
Growth (TTM | estimate)
Revenue
142.5% | 62.4%
EBITDA
60.8% | 1,979.0%
EBIT
43.1% | -
Net Income
66.5% | -
Free Cash Flow
122.1%
Margin (TTM | estimate)
Gross
82.1%
EBITDA
-3.1% | -
EBIT
-6.6%
Net
-5.7% | -
Free Cash Flow
2.7%
More
EPS
CHF-0.1
FCF per Share
CHF0.1
Short interest
-
Employees
122
Rev per Employee
CHF610.0k
Show more

Is Kuros Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Kuros Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Kuros Biosciences forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Kuros Biosciences forecast:

Buy
86%
Hold
14%

Financial data from Kuros Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
75 75
143% 143%
100%
- Direct Costs 13 13
47% 47%
18%
62 62
183% 183%
82%
- Selling and Administrative Expenses 60 60
105% 105%
80%
- Research and Development Expense 6.92 6.92
53% 53%
9%
-2.34 -2.34
61% 61%
-3%
- Depreciation and Amortization 2.61 2.61
4% 4%
3%
EBIT (Operating Income) EBIT -4.95 -4.95
43% 43%
-7%
Net Profit -4.25 -4.25
66% 66%
-6%

In millions CHF.

Don't miss a Thing! We will send you all news about Kuros Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Christopher Fair
Employees 122
Founded 2000
Website kurosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today